DK4010082T5 - Multispecifikke antistoffer mod variabel anti-tcr-delta 1 - Google Patents

Multispecifikke antistoffer mod variabel anti-tcr-delta 1 Download PDF

Info

Publication number: DK4010082T5
Authority: DK; Denmark
Prior art keywords: tcr; delta; antibodies against; multispecific antibodies; variable anti
Prior art date: 2020-08-14

Application number

DK21756070.5T

Other languages

English (en)

Other versions

DK4010082T4 (en

DK4010082T3 (da

Inventor

Mark Uden

Mihriban Tuna

Natalie Mount

Robert Good

Joshua Freedman

Shefali Bhumbra

Oliver Nussbaumer

Raj Jaysukhlal Mehta

Original Assignee

Gammadelta Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-08-14

Filing date

2021-08-14

Publication date

2024-08-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4010082(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-08-14 Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en

2021-02-17 Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en

2021-02-17 Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en

2021-08-14 Application filed by Gammadelta Therapeutics Ltd filed Critical Gammadelta Therapeutics Ltd

2023-04-03 Publication of DK4010082T3 publication Critical patent/DK4010082T3/da

2024-08-05 Application granted granted Critical

2024-08-05 Publication of DK4010082T5 publication Critical patent/DK4010082T5/da

2026-02-16 Publication of DK4010082T4 publication Critical patent/DK4010082T4/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Oncology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Steroid Compounds (AREA)

DK21756070.5T 2020-08-14 2021-08-14 Multispecifikke antistoffer mod variabel anti-tcr-delta 1 DK4010082T4 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
PCT/GB2020/051959 WO2021032963A1 (en)	2019-08-16	2020-08-14	Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en)	2021-02-17	2021-02-17	Multispecific anti-TCR delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en)	2021-02-17	2021-02-17	Anti-TRC delta variable 1 antibodies
PCT/IB2021/057509 WO2022034562A1 (en)	2020-08-14	2021-08-14	Multispecific anti-tcr delta variable 1 antibodies

Publications (3)

Publication Number	Publication Date
DK4010082T3 DK4010082T3 (da)	2023-04-03
DK4010082T5 true DK4010082T5 (da)	2024-08-05
DK4010082T4 DK4010082T4 (en)	2026-02-16

Family

ID=80247426

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK21756070.5T DK4010082T4 (en)	2020-08-14	2021-08-14	Multispecifikke antistoffer mod variabel anti-tcr-delta 1
DK23187269.8T DK4269444T5 (da)	2020-08-14	2021-08-14	Multispecifikke antistoffer mod variabel anti-tcr-delta 1

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK23187269.8T DK4269444T5 (da)	2020-08-14	2021-08-14	Multispecifikke antistoffer mod variabel anti-tcr-delta 1

Country Status (18)

Country	Link
EP (7)	EP4218932A3 (da)
JP (1)	JP7847579B2 (da)
KR (1)	KR20230083267A (da)
CN (1)	CN116209456A (da)
AU (1)	AU2021323512A1 (da)
BR (1)	BR112023002741A2 (da)
CA (1)	CA3188682A1 (da)
CO (1)	CO2023003009A2 (da)
DK (2)	DK4010082T4 (da)
ES (2)	ES2993071T3 (da)
FI (2)	FI4269444T3 (da)
IL (1)	IL300517A (da)
LT (2)	LT4269444T (da)
MX (1)	MX2023001728A (da)
PL (2)	PL4010082T5 (da)
PT (2)	PT4010082T (da)
SI (2)	SI4010082T1 (da)
WO (1)	WO2022034562A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT4269444T (lt)	2020-08-14	2024-09-25	GammaDelta Therapeutics Limited	Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
JP2025519645A (ja) *	2022-06-23	2025-06-26	ラヴァ・セラピューティクス・エヌ・ヴイ	Ｔ細胞依存性多重特異性化合物のアッセイ
EP4680729A1 (en) *	2023-03-17	2026-01-21	Legend Biotech Ireland Limited	Methods of culturing v delta 1 t cells
WO2025147597A1 (en) *	2024-01-05	2025-07-10	Eugit Therapeutics, Inc.	Targeting payloads
WO2025191133A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2546268A1 (en)	2011-07-13	2013-01-16	F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H.	Internalising immunoglobulin
WO2015063069A1 (en) *	2013-10-28	2015-05-07	Benjamin Felder	Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) *	2015-04-15	2015-05-27	Tc Biopharm Ltd	Gamma delta T cells and uses thereof
AU2016274633B2 (en)	2015-06-09	2022-04-21	Gammadelta Therapeutics Ltd	Methods for the production of TCR gamma delta+ T cells
CN108137691B (zh) *	2015-09-02	2021-10-19	耶路撒冷希伯来大学伊萨姆研究发展有限公司	特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
EP4148124A1 (en)	2015-10-30	2023-03-15	Cancer Research Technology Limited	Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
EP3454870A4 (en)	2016-05-12	2020-03-04	Adicet Bio Inc.	METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
GB201612520D0 (en)	2016-07-19	2016-08-31	F-Star Beta Ltd	Binding molecules
CA3032304A1 (en)	2016-07-29	2018-02-01	New York University	Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en)	2017-05-15	2020-01-28	Google Llc	Near-eye display with extended effective eyebox via eye tracking
EP3645050A4 (en)	2017-06-25	2021-08-11	Systimmune, Inc.	Multi-specific antibodies and methods of making and using thereof
US10519236B2 (en)	2018-01-23	2019-12-31	New York University	Antibodies specific to delta 1 chain of T cell receptor
WO2020060406A1 (en)	2018-09-19	2020-03-26	Lava Therapeutics B.V.	Novel bispecific antibodies for use in the treatment of hematological malignancies
GB201818243D0 (en)	2018-11-08	2018-12-26	Gammadelta Therapeutics Ltd	Methods for isolating and expanding cells
US12084500B2 (en) *	2019-01-23	2024-09-10	New York University	Antibodies specific to delta 1 chain of T cell receptor
CN113993893A (zh) *	2019-02-01	2022-01-28	拉法医疗有限公司	新cd40结合抗体
JP7730295B2 (ja)	2019-04-08	2025-08-27	メモリアルスローンケタリングキャンサーセンター	Ｃｄ１９抗体およびこれを使用する方法
US20220290101A1 (en)	2019-08-16	2022-09-15	GammaDelta Therapeutics Limited	Ex vivo gamma delta t cell populations
CA3145523A1 (en) *	2019-08-16	2021-02-25	GammaDelta Therapeutics Limited	Therapeutic uses of anti-tcr delta variable 1 antibodies
LT4269444T (lt)	2020-08-14	2024-09-25	GammaDelta Therapeutics Limited	Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
TW202246338A (zh)	2021-02-17	2022-12-01	英商適應生物治療有限公司	抗ＴＣＲδ可變1抗體

2021
- 2021-08-14 LT LTEP23187269.8T patent/LT4269444T/lt unknown
- 2021-08-14 PL PL21756070.5T patent/PL4010082T5/pl unknown
- 2021-08-14 BR BR112023002741A patent/BR112023002741A2/pt unknown
- 2021-08-14 MX MX2023001728A patent/MX2023001728A/es unknown
- 2021-08-14 EP EP23153152.6A patent/EP4218932A3/en active Pending
- 2021-08-14 CN CN202180069269.3A patent/CN116209456A/zh active Pending
- 2021-08-14 WO PCT/IB2021/057509 patent/WO2022034562A1/en not_active Ceased
- 2021-08-14 EP EP23187272.2A patent/EP4269445B1/en active Active
- 2021-08-14 EP EP23187273.0A patent/EP4269446B1/en active Active
- 2021-08-14 CA CA3188682A patent/CA3188682A1/en active Pending
- 2021-08-14 JP JP2023510439A patent/JP7847579B2/ja active Active
- 2021-08-14 DK DK21756070.5T patent/DK4010082T4/da active
- 2021-08-14 SI SI202130032T patent/SI4010082T1/sl unknown
- 2021-08-14 PT PT217560705T patent/PT4010082T/pt unknown
- 2021-08-14 LT LTEPPCT/IB2021/057509T patent/LT4010082T/lt unknown
- 2021-08-14 EP EP23187270.6A patent/EP4265642B1/en active Active
- 2021-08-14 DK DK23187269.8T patent/DK4269444T5/da active
- 2021-08-14 AU AU2021323512A patent/AU2021323512A1/en active Pending
- 2021-08-14 SI SI202130192T patent/SI4269444T1/sl unknown
- 2021-08-14 ES ES23187269T patent/ES2993071T3/es active Active
- 2021-08-14 IL IL300517A patent/IL300517A/en unknown
- 2021-08-14 EP EP23187271.4A patent/EP4265643B1/en active Active
- 2021-08-14 KR KR1020237005145A patent/KR20230083267A/ko active Pending
- 2021-08-14 FI FIEP23187269.8T patent/FI4269444T3/fi active
- 2021-08-14 EP EP21756070.5A patent/EP4010082B9/en active Active
- 2021-08-14 FI FIEP21756070.5T patent/FI4010082T4/fi active
- 2021-08-14 PT PT231872698T patent/PT4269444T/pt unknown
- 2021-08-14 EP EP23187269.8A patent/EP4269444B1/en active Active
- 2021-08-14 PL PL23187269.8T patent/PL4269444T3/pl unknown
- 2021-08-14 ES ES21756070T patent/ES2943063T3/es active Active
2023
- 2023-03-13 CO CONC2023/0003009A patent/CO2023003009A2/es unknown

Also Published As

Publication number	Publication date
DK4010082T4 (en)	2026-02-16
PT4010082T (pt)	2023-04-26
EP4265642B1 (en)	2024-06-26
EP4218932A2 (en)	2023-08-02
FI4010082T3 (fi)	2023-04-04
AU2021323512A1 (en)	2023-04-13
LT4269444T (lt)	2024-09-25
EP4010082B1 (en)	2023-01-25
FI4269444T3 (fi)	2024-09-20
PL4010082T3 (pl)	2023-05-29
EP4265642A2 (en)	2023-10-25
EP4265643A2 (en)	2023-10-25
DK4269444T3 (en)	2024-08-19
BR112023002741A2 (pt)	2023-10-10
DK4010082T3 (da)	2023-04-03
KR20230083267A (ko)	2023-06-09
IL300517A (en)	2023-04-01
WO2022034562A1 (en)	2022-02-17
EP4218932A3 (en)	2023-09-27
ES2943063T3 (es)	2023-06-08
EP4010082B2 (en)	2025-12-31
LT4010082T (lt)	2023-03-10
FI4010082T4 (fi)	2026-03-24
EP4269446A3 (en)	2024-02-14
EP4265643A3 (en)	2024-02-14
MX2023001728A (es)	2023-04-20
EP4269445B1 (en)	2024-06-26
PT4269444T (pt)	2024-09-05
CO2023003009A2 (es)	2023-03-17
EP4269444A3 (en)	2024-02-14
EP4269446A2 (en)	2023-11-01
SI4269444T1 (sl)	2024-10-30
DK4269444T5 (da)	2024-08-26
EP4269444B1 (en)	2024-06-26
EP4269446B1 (en)	2024-06-26
JP7847579B2 (ja)	2026-04-17
ES2993071T3 (en)	2024-12-20
PL4269444T3 (pl)	2025-01-13
CN116209456A (zh)	2023-06-02
JP2023537534A (ja)	2023-09-01
EP4269445A3 (en)	2024-02-14
EP4010082B9 (en)	2026-03-04
EP4265642A3 (en)	2024-02-14
PL4010082T5 (pl)	2026-03-09
EP4265643B1 (en)	2024-06-26
CA3188682A1 (en)	2022-02-17
EP4269444A2 (en)	2023-11-01
EP4010082A1 (en)	2022-06-15
SI4010082T1 (sl)	2023-04-28
EP4269445A2 (en)	2023-11-01

Publication	Publication Date	Title
DK3872091T3 (da)	2023-09-11	Antistoffer mod sars-cov-2
DK4010082T5 (da)	2024-08-05	Multispecifikke antistoffer mod variabel anti-tcr-delta 1
CR20230573A (es)	2024-05-07	ANTICUERPOS ANTI-SIRP-alfa
EP4293025C0 (en)	2025-10-29	COMPOSED WITH 4-AMINOQUINAZOLINE
DK4214240T3 (da)	2024-11-18	Anti-ccr8-antistoffer
DK3946179T4 (da)	2025-09-08	Stomiposer
EP4239011A4 (en)	2024-09-04	Polyamide
UA45074S (uk)	2022-05-26	1. навушники
EP4300176A4 (en)	2025-02-12	DECORATIVE FILM
IL310245A (en)	2024-03-01	Anti-hla-g antibodies
EP4392455A4 (en)	2025-08-20	ANTI-CD-25 ANTIBODIES
EP4455217A4 (en)	2025-11-26	POLYAMIDE COMPOSITION
EP4455218A4 (en)	2025-11-26	POLYAMIDE COMPOSITION
EP4455214A4 (en)	2025-11-26	POLYAMIDE COMPOSITION
DK4172199T3 (da)	2025-08-18	Alfa-synuklein-protofibril-bindende antistoffer
EP3963324A4 (en)	2023-07-05	Immunosensor
JP1746772S (ja)	2023-06-20	引き出し内オーガナイザー
EP4431606A4 (en)	2025-11-26	ANTI-EPHA4 ANTIBODIES
IL313590A (en)	2024-08-01	Compounds
IL309352A (en)	2024-02-01	Improved film
EP4311082A4 (en)	2024-11-27	COMPONENT
EP4098693A4 (en)	2024-03-13	POLYAMIDE COMPOSITION
PT4038149T (pt)	2023-05-29	Compostos anti-incrustação
EP4399932C0 (en)	2025-02-12	OVERLAYED TRANSMISSIONS ORCHESTRATED BY AP
EP3976027A4 (en)	2023-01-11	FACTOR XI ACTIVATION INHIBITORS